We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+43.32%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
+$297M
Cap. Flow
+$58.3M
Cap. Flow %
4.28%
Top 10 Hldgs %
45.16%
Holding
305
New
90
Increased
79
Reduced
51
Closed
35

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$31.8M
2
CLDX icon
Celldex Therapeutics
CLDX
+$14.2M
3
IVA
Inventiva
IVA
+$12.6M
4
TERN
Terns Pharmaceuticals
TERN
+$12.3M
5
ABUS icon
Arbutus Biopharma
ABUS
+$11.3M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$94.2M
2
ETNB
89bio
ETNB
+$31.1M
3
BIOA
BioAge Labs
BIOA
+$15.5M
4
MTSR
Metsera Inc
MTSR
+$7.98M
5
IVVD icon
Invivyd
IVVD
+$7.22M

Sector Composition

Rank Sector Weight
1 Healthcare 88.69%
2 Financials 1.72%
3 Real Estate 0.12%
4 Communication Services 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HELP
101
Cybin Inc
HELP
$688M
$1.95M 0.14%
238,390
+205,112
+616% +$1.32M
SLNO
102
DELISTED
Soleno Therapeutics
SLNO
$1.94M 0.14%
41,830
+16,600
+66% +$910K
ABOS icon
103
Acumen Pharmaceuticals
ABOS
$165M
$1.88M 0.14%
891,183
– –
ACRS icon
104
Aclaris Therapeutics
ACRS
$851M
$1.85M 0.14%
613,986
+240,304
+64% +$607K
PFE icon
105
Pfizer
PFE
$149B
$1.8M 0.13%
72,400
+28,000
+63% +$706K
BIOA
106
BioAge Labs
BIOA
$517M
$1.79M 0.13%
135,560
-1,744,513
-93% -$15.5M
ALKS icon
107
Alkermes
ALKS
$8.11B
$1.78M 0.13%
63,700
+7,500
+13% +$225K
GMED icon
108
Globus Medical
GMED
$11B
$1.75M 0.13%
+20,100
New +$1.53M
ALEC icon
109
Alector
ALEC
$203M
$1.73M 0.13%
+1,108,000
New +$1.97M
RCKT icon
110
Rocket Pharmaceuticals
RCKT
$387M
$1.67M 0.12%
475,800
-100,000
-17% -$342K
WW
111
WW International
WW
$169M
$1.67M 0.12%
57,100
+4,650
+9% +$130K
AQST icon
112
PUT
Aquestive Therapeutics
AQST
$492M
$1.64M 0.12%
+254,000
New +$1.58M
SMMT icon
113
Summit Therapeutics
SMMT
$10.8B
$1.61M 0.12%
91,869
-11,100
-11% -$209K
CCIIU
114
Cohen Circle Acquisition Corp II Unit
CCIIU
$1.56M 0.11%
150,000
– –
SUPN icon
115
Supernus Pharmaceuticals
SUPN
$2.72B
$1.48M 0.11%
29,742
+15,324
+106% +$745K
GOSS icon
116
PUT
Gossamer Bio
GOSS
$87.2M
$1.44M 0.11%
+463,200
New +$1.32M
INSP icon
117
Inspire Medical Systems
INSP
$1.7B
$1.38M 0.1%
15,000
+9,000
+150% +$861K
NRIX icon
118
Nurix Therapeutics
NRIX
$2.62B
$1.37M 0.1%
72,070
+40,870
+131% +$587K
JAZZ icon
119
Jazz Pharmaceuticals
JAZZ
$16.7B
$1.36M 0.1%
8,000
+5,500
+220% +$843K
OABI icon
120
OmniAb
OABI
$325M
$1.3M 0.1%
702,190
-388,438
-36% -$675K
OMER icon
121
PUT
Omeros
OMER
$952M
$1.29M 0.09%
+75,000
New +$646K
TNGX icon
122
Tango Therapeutics
TNGX
$4.72B
$1.24M 0.09%
+140,021
New +$1.21M
ADGM
123
Adagio Medical Holdings
ADGM
$16.3M
$1.21M 0.09%
+1,159,614
New +$1.38M
KNSA icon
124
Kiniksa Pharmaceuticals
KNSA
$5.97B
$1.19M 0.09%
28,728
-46,459
-62% -$1.86M
SYRE icon
125
Spyre Therapeutics
SYRE
$9.12B
$1.12M 0.08%
34,051
– –
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, ADAR1 Capital Management held 305 positions worth $1.36B, up 28% from $1.06B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

ADAR1 Capital Management deployed $58.3M of net new capital in Q4 2025, opening 90 new positions and adding to 79 existing holdings. Its largest new stake was Inventiva: 2,709,846 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $94.2M trimmed.

  • ADAR1 Capital Management's largest Q4 2025 buy was Inventiva: 2,709,846 shares worth $12.6M.
  • ADAR1 Capital Management added most to Avidity Biosciences in Q4 2025, an estimated $31.8M increase.
  • ADAR1 Capital Management's biggest Q4 2025 reduction was Keros Therapeutics, cutting an estimated $94.2M.
  • ADAR1 Capital Management fully exited 89bio in Q4 2025, selling an estimated $31.1M.
  • ADAR1 Capital Management's ten largest holdings make up 45% of its $1.36B portfolio in Q4 2025.
  • ADAR1 Capital Management opened 90 new positions and closed 35 in Q4 2025.
  • ADAR1 Capital Management's portfolio value rose 28% quarter-over-quarter to $1.36B.

Based on ADAR1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.